Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Gilead Sciences, Inc. GILD

Healthcare  —  Drug Manufacturers General
150.93 1.24 0.83% as of 25 Sep
Market cap
$183.2B
P/E
0.0×
S&P 500 Member Dividend Champion (10y)
Indexes indicate stock being part of an index,
Growth Flags show if company had growth for consecutive years
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Gilead Sciences, Inc. (GILD) Price to free cash flow

As of 25 September 2026, Gilead Sciences, Inc. (GILD) trades at a price to free cash flow of 14.5×. Over the past ten years it has ranged from 5.1× (December 2016) to 20.5× (February 2026); the current reading is higher than 91% of that period. That is below the Drug Manufacturers General industry median of 17.7× and below the Healthcare sector median of 19.5×.

Price to free cash flow, daily

Annual

Period Price to free cash flow Change
FY2025 16.1× 44.46%
FY2024 11.2× (20.15%)
FY2023 14.0× 9.00%
FY2022 12.8× 52.16%
FY2021 8.4× (13.35%)
FY2020 9.7× (1.80%)
FY2019 9.9× (8.66%)
FY2018 10.9× 26.80%
FY2017 8.6× 40.58%
FY2016 6.1× (15.68%)

Quarterly

Period Price to free cash flow Change
Jun 2026 12.1× (28.29%)
Mar 2026 16.9× 4.79%
Dec 2025 16.1× 7.22%
Sep 2025 15.1× 2.21%
42 more quarters

Against its own ten years

Low 5.1× High 20.5×
Ten-year median 10.6×
Current reading's percentile 91

Price to free cash flow against peers

Company Price to free cash flow
SNY Sanofi compare 6.8×
BMY Bristol Myers Squibb Company compare 11.2×
GSK GSK PLC Sponsored ADR compare 12.9×
GILD Gilead Sciences, Inc. 14.5×
PFE Pfizer Inc. compare 16.0×
NVS Novartis AG compare 18.3×
NVO Novo Nordisk A/S compare 22.6×
AMGN Amgen Inc. compare 23.0×
AZN AstraZeneca PLC compare 41.2×
Drug Manufacturers General industry median 17.7×
Healthcare sector median 19.5×
Market median 14.0×

What Price to free cash flow is

Price to Free Cash Flow Ratio shows how much investors pay for each dollar of cash a company generates after its capital spending.

Stock Price ÷ ((Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM)) ÷ (Shares (Basic, Weighted) (latest quarter)))

The full definition of Price to free cash flow →

More on GILD